---
document_datetime: 2023-09-21 17:58:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/onsenal-epar-procedural-steps-taken-authorisation_en.pdf
document_name: onsenal-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5406958
conversion_datetime: 2025-12-22 12:29:25.742169
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

•

•

Medicinal product no longer authorised The applicant Pharmacia - Pfizer EEIG submitted on 31 October 2001 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) through the centralised procedure for Onsenal, which was designated as an orphan medicinal product (EU/3/01/070) on 20 November 2001. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr P. Rossi Co-Rapporteur: Dr M. Ainsworth Orphan Drugs: Celecoxib was designated as an orphan medicinal product in the following indication: Treatment of Familial Adenomatous Polyposis (FAP). Scientific Advice: The applicant did not seek scientific advice at the CPMP. Licensing status: Celecoxib  has  been  given  a  Marketing  Authorisation  in  all  EU  countries,  through  the  Mutual Recognition Procedure, for the indication 'symptomatic relief in the treatment of osteoarthritis (OA) or rheumatoid arthritis (RA)'. Celecoxib has been given a Marketing Authorisation worldwide for the OA/RA indication (pending in Japan)  and  for  the  Familial  Adenomatous  Polyposis  (FAP)  indication  in  the  following  countries: Argentina,  Australia,  Brazil,  Chile,  Hong  Kong,  Korea,  Mexico,  Philippines,  USA  and  Venezuela (pending in Canada, Colombia, Malaysia, New Zealand, Peru, Singapore and Uruguay). 2. Steps taken for the assessment of the product · The procedure started on 20 November 2001. · The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 4 February 2002.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 30 January 2002. · During  the  meeting  on  19  -  21  March  2002  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 22 March 2002. · The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 14 June 2002. The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 29 August 2002. During the CPMP meeting on 17 - 19 September 2002 the CPMP adopted a list of outstanding issues to be addressed by the applicant in writing and if necessary in an oral explanation. The list of outstanding issues was sent to the applicant on 20 September 2002. · The applicant provided written information on these outstanding issues to all CPMP members on 28 November 2002.

- The  Rapporteur/Co-Rapporteurs'  joint  review  on  the  applicant's  responses  to  the  list  of outstanding issues was circulated to all CPMP members on 7 January 2003.

<!-- image -->

<div style=\"page-break-after: always\"></div>

- During the CPMP meeting on 21 - 23 January 2003, outstanding issues were addressed by the applicant during a hearing before the CPMP on 22 January 2003.
- During the meeting on 21 - 23 January 2003 the CPMP adopted a list of outstanding issues, to be addressed by the applicant in writing. The list of outstanding issues was sent to the applicant on 23 January 2003.
- Medicinal product no longer authorised · The applicant provided written information on these outstanding issues to all CPMP members on 28 February 2003. · The Rapporteur/Co-Rapporteurs' joint review on the responses to the list of outstanding issues was circulated to all CPMP members on 7 March 2003. · During the meeting on 18 - 19 March 2003 the CPMP adopted a list of outstanding issues, to be addressed by the applicant in writing. The list of outstanding issues was sent to the applicant on 20 March 2003. · The applicant provided written information on these outstanding issues to all CPMP members on 30 April 2003. · In the margin of the CPMP meeting on 20 - 22 May 2003, an ad-hoc clinical expert meeting took place on 19 May 2003 and a report was adopted by the CPMP on 22 May 2003 (Annex 10). · During  the  CPMP  meeting  on  24  -  26  June  2003,  outstanding  issues  were  addressed  by  the applicant on 24 June 2003 during an oral hearing before the CPMP. · During the meeting on 24 - 26 June 2003 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation under exceptional circumstances to Onsenal on 26 June 2003. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 17 October 2003.

<!-- image -->